Navigation Links
With new method, CSHL team is able to infer how tumors evolve and spread
Date:3/13/2011

tumor, into which the body's own immune cells have migrated and perhaps also toxic chemotherapy drugs have been introduced. This is one way of understanding why cancers are so tough to combat, and why they are able to survive even the application of cytotoxic therapies. In short, cancer cells are often able to evolve around these.

It has been theorized that genetically heterogeneous tumor cell populations become mixed via gradual evolution. The CSHL team, in contrast, suggests the evolution is likely punctuated. "It's a very complicated matter to try to determine a given tumor's genetic evolution," says Hicks of the CSHL team. "The different groups of cells are geographically and anatomically intertwined. In evolutionary terms, you might think of them as distinct but intermixed 'tribes,' or subspecies. It's important to keep in mind that tumors are chaotic places. There's always a certain amount of chaotic evolution taking place, some of it reflected in rearrangement of chromosomes and some in single base-pair changes in the DNA of individual tumor cells. But our results, although based so far on a limited sample size, suggest that major clonal expansion events are relatively infrequent and may provide accessible targets for targeted treatments"

Implications for understanding metastasis

The second breast cancer sample analyzed by the team was of a single genomic type, but the team was able to determine that the liver metastasis to which it had given rise was very closely related, in genomic terms. "The data suggest the primary tumor mass formed by a single clonal expansion and that one of the cells from this event subsequently seeded the metastatic tumor, with little further evolution," according to Navin. "Although closely related, primary and metastatic tumor cells were cleanly separated, indicating to us that the two populations had not mixed" since the origin of the metastasis. Further, he noted, "differences in the pro
'/>"/>

Contact: Peter Tarr
tarr@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Why chemotherapy causes more infertility in women than in men
2. Mildew-resistant and infertile
3. Reproductive health: Checkerboard of infertility treatment in Europe
4. Swimming upstream: Molecular approaches to better understand male infertility
5. U of I study: Lack of omega-3 fatty acid linked to male infertility
6. Researchers identify gene with possible link to infertility in mice
7. ESHREs first workshop on male infertility in Thessaloniki
8. Small RNAs can play critical roles in male infertility/contraception
9. Fireflies and jellyfish help illuminate quest for cause of infertility
10. Miscarriage and infertility treatment increase pre-eclampsia risk
11. Proteins in sperm unlock understanding of male infertility says new study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
(Date:7/9/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/98rrmr/biometrics_for ... "Biometrics for Banking; Market & Technology Analysis, Adoption ... offering. The adoption for banking purposes ... the forecast is that by 2020 it will ... in delivering biometric systems to the banking industry. ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... discovered that a fundamental building block in the ... identically, on a separate branch of the evolutionary ... originated at least 420 million years ago. ... gymnosperms, the group that includes conifers, ginkgos and ...
... Massachusetts Medical School (UMMS) report today on a new ... individual genes for inactivationa technique with broad potential implications ... scientific teams at UMMS, one led by Scot A. ... Gene Function & Expression and the Department of Biochemistry ...
... Centre (LUMC) are the first to determine the DNA ... European whose DNA sequence has been determined. This has ... special press conference at Bessensap, a yearly meeting of ... Following in-depth analysis, the sequence will be made ...
Cached Biology News:When plants 'think' alike 2New technique allows targeted inactivation of genes in research model 2Leiden scientists sequence first female DNA 2
(Date:7/30/2015)... Pa. , July 30, 2015  Discovery ... that it has received the second $1.0M tranche ... Innovation Research (SBIR) grant valued at up to ... company,s aerosolized KL4 surfactant as a potential medical ... injury.  Discovery Labs was awarded an initial $1.0 ...
(Date:7/29/2015)... 2015 Sanofi, un leader ... résultats pour le premier semestre 2015. Le Directeur ... Visionner l,interview vidéo et lire la ... Au sommaire de l,interview :  ... croissance - Diabète - ...
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... Company,s Chief Financial Officer has resigned.  The Company has ... Officer who retired in December 2014, as full time ... permanent successor.     Andy Ashworth began ... ensure a smooth transition.  Andy was the Company,s CFO ...
(Date:7/29/2015)... DUBLIN , July 29, 2015 ... ) has announced the addition of the ... to their offering. The Global Biosimilars ... study of the rapidly growing biosimilars market. With ... industry striving to minimize costs, biosimilars are being ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3
... SETAUKET, N.Y., May 25, 2011 John S. Kovach, ... Biotechnology Holdings, Inc. (LIXT.PK), announces the appointment of  Robert ... of Directors. Dr. Royds is Chair of ... a leading clinical research organization, which he founded in ...
... a Phase 2 multicenter, randomized, double-blind, proof-of-concept and ... 136) improved signs and symptoms of rheumatoid arthritis ... with methotrexate (MTX).  Findings from Part A of ... League Against Rheumatism (EULAR) Congress showed that a ...
... May 25, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... today jointly announced that Watson has acquired the ... for EUR 400 million ($562 million) in cash ... the acquisition, Watson gains a leading generic product ...
Cached Biology Technology:Lixte Biotechnology Holdings Announces New Appointment to Board of Directors 2Lixte Biotechnology Holdings Announces New Appointment to Board of Directors 3Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis 2Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis 3Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis 4Watson Acquires Specifar Pharmaceuticals 2Watson Acquires Specifar Pharmaceuticals 3Watson Acquires Specifar Pharmaceuticals 4Watson Acquires Specifar Pharmaceuticals 5Watson Acquires Specifar Pharmaceuticals 6
Recombinant Human Erythropoietin (Tissue Culture Grade)...
One-step, microplate or cuvet, colorimetric, detection range 0.78 ug/dL to 65 ug/dL Zn in serum, plasma, urine, saliva etc. Procedure: 10 min....
Human PDGF R beta MAb (Clone # PR7212)...
Recombinant Mouse IL-23, CF...
Biology Products: